



February 13, 2025

To
Department of Corporate Affairs- Listing
BSE Limited
PhirozJeeJeebhoy Towers,
Dalal Street, Fort Mumbai-400001

Scrip Code: 530313 [KIMIABL]

Sub: Outcome of the Board Meeting held on Thursday, February 13, 2025 for Unaudited Financial Results for the quarter and nine months ended 31st December, 2024 along with the Limited Review Report thereon

Dear Sir/Ma'am,

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations") read with Para A of Part A of Schedule III of the Listing Regulations, we wish to inform you that the Board of Directors in their meeting held today i.e., Thursday, February 13, 2025 inter-alia, has considered and approved the Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2024 along with the Limited Review Report thereon as attached herewith.

The Board Meeting held today commenced at 05:30 P.M. and concluded at 06:00 P.M.

Kindly take the same on record.

Thanking You,
Yours faithfully,

For **KIMIA BIOSCIENCES LIMITED**

Sameer
Goel

Digitally signed by
Sameer Goel
Date: 2025.02.13
18:02:28 +05'30'

Sameer Goel
Managing Director & Chief Executive Officer
Place: New Delhi

KIMIA BIOSCIENCES LIMITED

Regd. Office/Works
Village Bhondsi, Damdama Lake Road,
Gurugram, Haryana-122102
Tel.: +91 9654746544, 9654206544

Corporate Office
974, 9th Floor, Aggarwal Millennium Tower-II
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA
Tel.: +91 11 47063600, 470630601

compliance.kimia@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.: L24239HR1993PLC032120

Sunil Suresh & Associates

CHARTERED ACCOUNTANTS

Off. : B-20/21, Ground Floor,
Fruit Garden, N.I.T.
Faridabad-121001
E-mail : cargs45@gmail.com

Review Report

To
The Board of Directors
Kimia Biosciences Limited
Village Bhondsi, Tehsil Sohna
Gurgaon Haryana-122102

1. We have reviewed the accompanying statement of unaudited financial results of Kimia Biosciences Limited (the "Company") for the quarter ended December 31, 2024 and year to date results for the period from April 01, 2024 to December 31, 2024 (the "Statement"), being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation, 2015"), which has been initialled by us for identification purposes.
2. The statement is the responsibility of the Company's Management which has been approved by the Board of Directors and prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sunil Suresh & Associates
FRN 011646N
Neeraj Kumar Arora
Partner



M. No. 510750
UDIN:- 25510750BHIEEX4124
Place:- Gurugram
Dated:- February 13, 2025

KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2024



S. No.	Particulars	Quarter ended			Nine months ended		Year Ended
		31/12/2024 (Unaudited)	30-09-2024 (Audited)	31/12/2023 (Unaudited)	31/12/2024 (Unaudited)	31/12/2023 (Unaudited)	31/03/2024 (Audited)
I	Revenue from Operations	3,009.91	2,817.86	2,614.46	8,067.70	7,457.48	10,487.65
II	Other Income	42.41	37.09	57.63	87.83	133.89	164.18
III	Total Income (I+II)	3,052.32	2,854.95	2,672.09	8,155.53	7,591.37	10,651.83
IV	Expenses:						
	a) Cost of materials consumed	1,318.64	1,746.35	2,018.14	4,562.21	4,879.49	6,735.80
	b) Change in inventories of finished goods and work-in-progress	377.11	(20.95)	(60.99)	81.59	710.09	789.73
	c) Employee benefits expenses	394.05	352.45	383.20	1,089.33	1,171.42	1,515.25
	d) Finance costs	100.77	103.93	131.12	315.54	370.62	504.98
	e) Depreciation and amortisation expense	81.56	78.64	81.88	249.98	247.40	329.23
	f) Other expenses	420.58	403.10	378.85	1,127.64	1,161.27	1,495.21
V	Total Expenses (IV)	2,692.71	2,663.52	2,932.20	7,426.29	8,540.29	11,370.20
VI	Profit/(loss) before exceptional items and Tax (III-V)	359.61	191.43	(260.11)	729.24	(948.92)	(718.37)
VII	Exceptional Items	-	-	-	-	-	-
VI	Profit/(loss) before tax (IV-V)	359.61	191.43	(260.11)	729.24	(948.92)	(718.37)
VII	Tax expenses:						
	a) Current Tax	(61.69)	31.95	-	-	-	-
	b) Deferred Tax charge / (credit)	(35.72)	(1.86)	(64.93)	(32.83)	(238.52)	(187.50)
VIII	Profit/(loss) for the period (VI-VII)	457.02	161.34	(195.18)	762.06	(710.40)	(530.87)
IX	Other Comprehensive Income						
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)						
	- Remeasurement of defined benefit plans	-	-	-	-	-	17.69
B.	Items that will be reclassified to Profit or Loss (Net of Tax)						
X	Total Comprehensive Income for the period (VIII+IX)	457.02	161.34	(195.18)	762.06	(710.40)	(513.18)
XI	Paid up equity share capital (Face value of Rs.1 per equity share)	473.13	473.13	473.13	473.13	473.13	473.13
XII	Other Equity						(440.03)
XIII	Earnings per equity share (not annualised)						
	Basic in Rs.	0.97	0.34	(0.41)	1.61	(1.50)	(1.12)
	Diluted in Rs.	0.97	0.34	(0.41)	1.61	(1.50)	(1.12)

Other Notes

- The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 13, 2024.

For KIMIA BIOSCIENCES LTD.
FOR KIMIA BIOSCIENCES LIMITED

Vipul
Director

Date : February 13, 2024
Place : New Delhi

Vipul Goel
Director
DIN: 00064274



KIMIA BIOSCIENCES LIMITED
Statement of Profit & Loss for the Year Ended December 31, 2024

	Note	For the Period ended Sept 30, 2024 6 Months)	For the Period ended (Dec 31, 2024 3 Months)	For the Period A December 31, 2024, (9 Months)	For the Period ended March 31, 2024
I REVENUE					
(a) Revenue from Operations	27	5,057.79	3,009.91	8,067.70	10,487.65
(b) Other Income	28	45.42	42.41	87.83	164.18
Total Income		5,103.21	3,052.32	8,155.53	10,651.83
II EXPENSES					
(a) Cost of Materials Consumed	29	3,243.57	1,318.64	4,562.21	6,735.80
(b) Changes in Inventories of Finished Goods and Work-in-Progress	30	(295.52)	377.11	81.59	789.73
(c) Employee Benefits Expense	31	695.28	394.05	1,089.33	1,515.25
(d) Finance Costs	32	214.77	100.77	315.54	504.96
(e) Depreciation and Amortization Expense	33	168.42	81.56	249.98	329.23
(f) Other Expenses	34	707.06	420.58	1,127.64	1,495.21
Total Expenses		4,733.58	2,692.71	7,426.29	11,370.20
III Profit / (Loss) before exceptional items and Tax (I-II)		369.63	359.61	729.24	(718.37)
IV Exceptional Items	35	-	-	-	-
V Profit / (Loss) before Tax (III-IV)		369.63	359.61	729.24	(718.37)
VI Tax Expense		7%	12%	9%	-7%
(a) Current Tax		61.69	(61.69)	-	-
(b) Deferred Tax Charge / (Credit)	19	2.90	(35.72)	(32.83)	(187.50)
Total Tax Expense		64.59	(97.41)	(32.83)	(187.50)
VII Profit / (Loss) for the year (III-IV)		305.04	457.02	762.06	(530.87)
VIII Other Comprehensive Income					
(a) (i) Items that will not be reclassified to profit or loss					
- Remeasurement of defined benefit plans		-	-	-	23.64
(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-	-	(5.95)
(b) (i) Items that will be reclassified to profit or loss		-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss		-	-	-	-
Total Other Comprehensive income (a+b)		-	-	-	17.69
VII Total comprehensive income for the year (V+VI)		305.04	457.02	762.06	(513.18)
VIII Earnings Per Share of ₹ 1 each					
(i) Basic (in ₹)	35	0.64	0.97	1.61	(1.12)
(ii) Diluted (in ₹)		0.64	0.97	1.61	(1.12)

Summary of significant accounting policies and other notes on Financial Statements

1 to 51

The accompanying notes are an integral part of the financial statements

As per our report of even date attached

For KIMIA BIOSCIENCES LTD.

For and on behalf of Board of Directors

Vipul Goel

Director

DIN: 00064274

Place : New Delhi

Vipul Goel
Director





KIMIA BIOSCIENCES LIMITED
BALANCE SHEET as at 31 December, 2024

	Note	As at Dec 31, 2024	As at March 31, 2024
ASSETS			
I Non-Current Assets			
(a) Property, Plant and Equipment	3	2,969.97	3,149.96
(b) Capital Work-in-Progress	3A	-	57.62
(c) Right of Use Assets	4	48.69	30.46
(c) Intangible Assets	4	2.02	4.09
(d) Deferred Tax Assets (Net)	19	611.26	578.43
(e) Financial Assets			
(i) Other Financial Assets	5	40.88	26.32
(f) Other Non-current Assets	6	-	9.03
Total Non-Current Assets		3,672.82	3,855.91
II Current Assets			
(a) Inventories	7	3,131.49	3,080.35
(b) Financial Assets			
(i) Investments	8	-	-
(ii) Trade Receivables	9	3,037.56	2,755.40
(iii) Cash and Cash Equivalents	10	18.40	14.76
(iv) Bank balances other than (iii) above	11	44.37	38.68
(v) Other Financial Assets	12	126.93	103.12
(c) Current Tax Assets (Net)	13	62.95	73.11
(d) Other Assets	14	90.14	75.33
Total Current assets		6,511.82	6,140.75
Total Assets		10,184.64	9,996.66
EQUITY AND LIABILITIES			
I Equity			
(a) Equity Share Capital	15	473.13	473.13
(b) Other Equity	16	322.03	(440.03)
Total Equity		795.16	33.10
II Non-Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	17	1,336.67	2,140.98
(ii) Lease Liabilities		32.49	18.45
(iii) Other Financial Liabilities	18	619.91	580.71
(b) Provisions	20	153.95	144.90
(c) Other Non-Current Liabilities	21	109.74	134.75
Total Non-Current Liabilities		2,252.76	3,019.79
III Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings	22	2,006.48	2,199.15
(ii) Lease Liabilities		17.89	12.13
(ii) Trade Payables	23		
- Total Outstanding due to Micro and Small Enterprises		4.73	4.95
- Total Outstanding due to other than Micro and Small Enterprises		4,107.83	3,993.87
(iii) Other Financial Liabilities	24	541.01	506.63
(b) Other Current Liabilities	25	459.17	224.39
(c) Provisions	26	-	2.65
Total Current Liabilities		7,137.11	6,943.77
Total Equity and Liabilities		10,185.04	9,996.66

Summary of significant accounting policies and other notes on Financial Statements

1 to 51

The accompanying notes are an integral part of these financial statements

As per our report of even date attached

For KIMIA BIOSCIENCES LTD.
For and on behalf of Board of Directors


Director

Vipul Goel
Director
DIN: 00064274
Place : New Delhi

